You are here

11-05-2017 | Portrait and illustration: Photo Evolutionary Biology group (Isabel Gordo) | llustration: Macrophages with Escherichia coli

New knowledge to fight back against antibiotic resistance

The use and misuse of antibiotics has accelerated the emergence of drug-resistant bacterial strains, threatening our ability to treat common diseases. EU-funded research has shed new light on the mechanisms behind these microbial mutations, with implications for our understanding of diseases and resistance to treatment.

01-04-2017 | © picture

Frontier science and business that makes a difference

Maria Brandão de Vasconcelos, together with her colleague Filipa Matos Baptista, Henrique Veiga-Fernandes (ERC grantee), Diogo Fonseca Pereira and Sílvia Arroz Madeira, founded StemCell2MAX in 2015. The company is a biotechnology start-up, specialised in cell based therapies, including novel solutions to multiply the scarcely available blood stem cells, addressing an enormous demand for research and cancer treatment. StemCell2MAX technology is based on Prof. Veiga-Fernandes's ground-breaking discoveries in hematopoietic stem cell biology.

Originally published in March 2017 as part of the multimedia campaign "ERC - 10 years – 10 portraits."

24-03-2017 | © picture

Riding a Trojan horse against cancer

Magdalena Król is Professor at the Faculty of Veterinary Medicine of the Warsaw University of Life Sciences (SGGW) in Poland. She specializes in cancer research. Since 2006 Professor Król and her team have been investigating canine mammary cancer with particular focus on cancer metastasis and tumor microenvironment. Now she develops innovative cell-based method of drug delivery to solid tumors. Her discoveries about interactions between immune cells and cancer cells may one day revolutionize the treatment of cancer.

Originally published in March 2017 as part of the multimedia campaign "ERC - 10 years – 10 portraits."

29-06-2016 | © picture

Stem cells: from frontier research project to promising spin-off company

Haematopoietic Stem Cells (HSCs) are blood cells located in the bone marrow. These cells are extensively used in research to develop treatments for many severe diseases, including HIV and multiple sclerosis, and their transplant is a key therapy for certain types of cancer like leukemia and multiple myeloma. However, the use of HSCs is seriously constrained by their limited availability since growing them in the lab does not produce very large quantities. There is therefore an urgent need for methods allowing scientists to multiply HSCs, without losing any of their properties.

21-01-2016 | © P Sankowski

Real-life problems realistically solved

Is a precise answer always better than a slightly less detailed one? Not necessarily. Some problems could take forever to compute and tie up vast IT capacity. Where solutions are needed urgently, e.g. in business or manufacturing, near-enough can be more than enough. ERC-funded research has produced a library of fast, powerful approximation algorithms.